ARIPO Signs MoU with Arterial Network to Promote and Protect Creativity in Africa

ARIPO and Arterial Network
Image Source: ARIPO Website

ARIPO recently announced that it has signed a Memorandum of Understanding (MoU) with Arterial Network in order to ensure cooperation in the area of copyright and related rights. The MoU was signed on May 2, 2018 at the ARIPO Headquarters in the presence of ARIPO Director General, Mr. Fernando dos Santos and the Chairman of the Arterial Network, Mr. Daves Guzha in the presence of the Arterial Network Secretary General Ms. Tojo Yharimanana. Also in attendance were ARIPO Executives and Heads of Departments.

According to ARIPO, the objective of this Agreement is to facilitate cooperation between the two organizations with a view to promoting creativity and the protection of creative works for the socio-cultural development of ARIPO member States, Arterial Network member States and Africa at large.

The two parties highlighted the value and importance of copyright and related rights to the growth of developing countries and the need to protect and defend the rights of artists and creative practitioners on the African continent in order to foster the sustainable development of the creative industry.

The Arterial Network is a vibrant pan-African network of civil society that brings together artists, organisation and institutions involved in the African creative sector. It supports arts through advocacy, capacity building, market access, knowledge management and information dissemination. It has 17 affiliates in in Mauritania, Morocco, Nigeria, Mali, Togo, Senegal, Seychelles, Uganda, Cameroon, Congo, Democratic Republic of Congo, Central African Republic, Chad, South Africa, Zimbabwe, Swaziland and Mozambique.

Print Friendly, PDF & Email
About Bob Aroture 564 Articles
Bob is a Senior Editor and Content Development Manager at Nigerian Law Intellectual Property Watch. He holds a BS degree, with a major in biochemistry. He works directly with the Newsroom Team. His focus areas are technology and innovation, and pharmaceutical technology. Email: